Based on recently published safety data, two clinical trials evaluating combinations of Tecentriq (atezolizumab) in multiple myeloma and follicular lymphoma patients were placed on partial clinical hold at…
News
Sellas Life Sciences’ cancer vaccine galinpepimut-S showed promising effects in patients with an aggressive form of multiple myeloma, researchers said in a presentation at…
The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy…
Poseida Therapeutics demonstrated that their new CAR T-cell treatment for multiple myeloma — P-BCMA-101 — possessed features that make it stand out in the…
Lab tests used to evaluate treatment response after a stem cell transplant for multiple myeloma could lead physicians to wrongfully believe that a patient is…
The U.S. Food and Drug Administration has ordered Bristol-Myers Squibb to put a hold on three clinical trials evaluating Opdivo (nivolumab) in combination with…
The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical trial testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory and an anti-cancer…
New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of…
Relapsed multiple myeloma patients who receive Kyprolis (carfilzomib) plus dexamethasone as their second-to-fourth treatment regimen survive a median of 7.6 months longer than those…
Patients with relapsed or treatment-resistant multiple myeloma, who have undergone several earlier treatment rounds, have a much poorer response to combination treatments including Darzalex (daratumumab)…
